J&J profit beats forecast, but drug sales dim
NEW YORK (Reuters) - Johnson & Johnson on Tuesday said second-quarter earnings beat Wall Street's expectations as strong demand for its medical devices and consumer products overshadowed negligible growth of prescription drugs.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=sMbfik" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=sMbfik)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=kPMSdJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=kPMSdJ) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=7BcB7j" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=7BcB7j) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=nGxHmj" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=nGxHmj)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/336037943" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/336037943/idUSWNAB068920080715